Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue

Acta Biomed. 2008 Dec;79(3):205-10.


Background and aim of the work: The authors have previously reported the use of Silymarin (a Silybum marianum standardized extract) as a promoter of milk production in cows. Due to the important psychological impact of hypogalactia in women after delivery, we evaluated the role of Silymarin as a safe and effective galactogogue for human species.

Methods: 50 healthy women during lactation were enrolled in order to verify the galactogogue role played by an oral treatment with micronized Silymarin (420 mg/day) in comparison with an undistinguishable placebo product.

Results: Women orally treated for 63 days with Silymarin showed a clear galactagogue role for the product with an increase of 85.94% of the daily milk production (placebo: +32.09%). No drop out, nor unwanted effects were reported in both groups. Compliance and tolerability were also very good.

Conclusions: Silymarin may be considered as a safe and effective herbal product that can be orally administered in order to improve the daily milk production in healthy women after delivery, without affecting milk quality.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Oral
  • Antioxidants / administration & dosage
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Breast Feeding
  • Data Interpretation, Statistical
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Lactation / drug effects*
  • Milk, Human / chemistry*
  • Safety
  • Silymarin / administration & dosage
  • Silymarin / pharmacology
  • Silymarin / therapeutic use*
  • Time Factors


  • Antioxidants
  • Silymarin